Method for the production of isoquinoline derivatives and their use as intermediates in the preparation of indole derivatives
申请人:TORAY INDUSTRIES, INC.
公开号:EP0735026A1
公开(公告)日:1996-10-02
An isoquinoline derivative represented by the general formula (101):
wherein R101 is a hydrogen atom or a C1-5 alkyl, C4-7 cycloalkylalkyl, C6-8 cycloalkenylalkyl, C7-14 aralkyl, C4-5 transalkenyl, allyl, furanyl-2-ylalkyl, thienyl-2-ylalkyl or R107OCO group (wherein R107 is a 2,2,2-trichloroethyl or benzyl group) or is a R108CO group (wherein R108 is a C1-5 alkyl, C3-6 cycloalkyl, C5-7 cycloalkenyl, phenyl, C7-13 aralkyl, C4-5 trans-alkenyl, vinyl, 2-furanyl or 2-thienyl group), R102, R103, R104 and R105 are each independently a hydrogen atom or a hydroxy, alkanoyloxy having up to 5 carbon atoms or C1-5 alkoxy group or wherein R102 and R103 jointly or R104 and R105 jointly may form oxo or R103 and R104 jointly may form a 1,3-dioxolan ring, R106 is a hydrogen atom or a hydroxy, C1-5 alkoxy or alkanoyloxy group having up to 5 carbon atoms and wherein the general formula (101) embraces a (+) form, a (-) form, and a (±) form, or a pharmacologically acceptable salt thereof; is prepared by oxidizing the carbamate form of an enamine represented by the general formula (103):
wherein R102, R103, R104, R105, R106 and R107 are as defined above, thereby forming an oxide represented by the general formula (101a):
wherein R102, R103, R104, R105, R106 and R107 are as defined above, and wherein the formula (101a) embraces a (+) form, a (-) form, and a (±) form; and optionally converting the group
to any of the other values of the group R101. The compounds are intermediates for the production of pharmaceutically useful indole derivatives.
由通式(101)代表的异喹啉衍生物:
其中 R101 是氢原子或 C1-5 烷基、C4-7 环烷基、C6-8 环烯基、C7-14 芳基、C4-5 反烯基、烯丙基、呋喃基-2-烷基、噻吩基-2-烷基或 R107OCO 基团(其中 R107 是 2,2、2-三氯乙基或苄基)或 R108CO 基团(其中 R108 是 C1-5 烷基、C3-6 环烷基、C5-7 环烯基、苯基、C7-13 芳基、C4-5 反式烯基、乙烯基、2-呋喃基或 2-噻吩基),R102、R103、R102、R103、R104 和 R105 各自独立地为氢原子或羟基、最多 5 个碳原子的烷酰氧基或 C1-5 烷氧基,或其中 R102 和 R103 共同或 R104 和 R105 共同可形成氧代或 R103 和 R104 共同可形成 1、3-二氧戊环,R106 是氢原子或具有最多 5 个碳原子的羟基、C1-5 烷氧基或烷酰氧基,其中通式 (101) 包含 (+) 形式、(-) 形式和 (±) 形式,或其药理上可接受的盐;通过氧化通式(103)代表的烯胺的氨基甲酸酯形式制备:
其中 R102、R103、R104、R105、R106 和 R107 如上定义,从而形成通式 (101a) 所代表的氧化物:
其中 R102、R103、R104、R105、R106 和 R107 如上所定义,式 (101a) 包含 (+) 形式、(-) 形式和 (±) 形式;并可选择地将基团转化为
转化为基团 R101 的任何其他值。这些化合物是生产药用吲哚衍生物的中间体。